Clinical Trial

Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 20, 2026 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
In previous clinical practice, 68Ga-Pentixafor PET/CT has demonstrated promising diagnostic utility in various neuroendocrine tumors by targeting CXCR4, a chemokine receptor overexpressed in several ACTH-secreting neoplasms. Building on this, and leveraging the Nuclear Medicine expertise at Peking Union Medical College Hospital, we aim to conduct a prospective observational study investigating the role of CXCR4-targeted PET/CT imaging in patients with confirmed or suspected Cushing's syndrome. This study will focus on evaluating the capability of \^68Ga-Pentixafor PET/CT to assist in the differential diagnosis of ACTH-dependent and ACTH-independent subtypes, as well as in the localization of primary lesions in challenging cases. Imaging performance will be assessed in comparison with conventional modalities and/or 68Ga-DOTATATE PET/CT when available.
Trial Details
NCT Number NCT07350707
Lead Sponsor Peking Union Medical College Hospital
Conditions Cushing s Syndrome
Enrollment 160 participants
Start Date 2023-06-12
Primary Completion 2026-03-01 (estimated)
Study Completion 2027-02-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-20